BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Zhang LT, Park JK. Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia? World J Nephrol 2015; 4(1): 138-147 [PMID: 25664256 DOI: 10.5527/wjn.v4.i1.138]
URL: https://www.wjgnet.com/2220-6124/full/v4/i1/138.htm
Number Citing Articles
1
Taymour Mostafa. Useful Implications of Low-dose Long-term Use of PDE-5 InhibitorsSexual Medicine Reviews 2016; 4(3): 270 doi: 10.1016/j.sxmr.2015.12.005
2
Kai Sun, Fengze Sun, Huibao Yao, Dongxu Zhang, Gang Wu, Tianqi Wang, Jipeng Wang, JiTao Wu. Efficacy and Safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to Monotherapies, in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction Associated With Benign Prostatic Hyperplasia: A Meta-AnalysisAmerican Journal of Men's Health 2020; 14(6): 155798832098018 doi: 10.1177/1557988320980180
3
Stamatios Katsimperis, Konstantinos Kapriniotis, Ioannis Manolitsis, Themistoklis Bellos, Panagiotis Angelopoulos, Patrick Juliebø-Jones, Bhaskar Somani, Andreas Skolarikos, Lazaros Tzelves. Early investigational agents for the treatment of benign prostatic hyperplasia’Expert Opinion on Investigational Drugs 2024; 33(4): 359 doi: 10.1080/13543784.2024.2326023
4
Igor Voznesensky, Eric Shaw, Kenneth J. DeLay, Faysal Yafi, Wayne J.G. Hellstrom. Benign Prostatic Hyperplasia Treatment Options and Their Effects on Sexual FunctionSexual Medicine Reviews 2017; 5(1): 87 doi: 10.1016/j.sxmr.2016.05.006
5
Kanika Gupta, Mona Yezdani, Tiffany Sotelo, Jeanny B Aragon-Ching. A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasiaExpert Opinion on Investigational Drugs 2015; 24(8): 1059 doi: 10.1517/13543784.2015.1048333
6
Mohamed Mahmoud Zaza, Adham Hussien Mohamed Hussien, Tarek Abdel-Majid Salem, Mohamed Hassan Ali Soliman. The efficacy of vardenafil and tamsulosin in treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomised clinical trialJournal of Clinical Urology 2024;  doi: 10.1177/20514158241227097
7
Hakan Öztürk. How close are PDE5 inhibitors to being successful in the treatment of BPH?The Journal of Clinical Pharmacology 2016; 56(4): 381 doi: 10.1002/jcph.623
8
Taymour Mostafa. Non-Sexual Implications of Phosphodiesterase Type 5 InhibitorsSexual Medicine Reviews 2017; 5(2): 170 doi: 10.1016/j.sxmr.2016.02.004
9
Mohamed Tharwat, Mohamed M. Elsaadany, Ahmed M. Lashin, Ahmed R. EL-Nahas. A randomized controlled trial evaluating sildenafil citrate in relieving ureteral stent-related symptomsWorld Journal of Urology 2018; 36(11): 1877 doi: 10.1007/s00345-018-2339-y
10
Hamidreza Baghani Aval, Zeinab Ameli, Mojtaba Ameli. Effectiveness of the addition of tadalafil to tamsulosin in the treatment of acute urinary retention in patients with benign prostatic hyperplasia: A randomized clinical trialUrologia Journal 2018; 85(2): 51 doi: 10.1177/0391560317749427
11
Robert A. Kloner, Paul Goggin, Irwin Goldstein, Geoffrey Hackett, Michael G. Kirby, Ian Osterloh, John D. Parker, Richard Sadovsky. A New Perspective on the Nitrate–Phosphodiesterase Type 5 Inhibitor InteractionJournal of Cardiovascular Pharmacology and Therapeutics 2018; 23(5): 375 doi: 10.1177/1074248418771896